Navigation Links
Aushon to Launch New Multiplex Immunoassay Platform
Date:5/21/2012

BILLERICA, Mass., May 21, 2012 /PRNewswire/ -- Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.  Aushon's ultra-precise microarray printing, novel assay design, astronomy-grade imaging and advanced analytics provide the sensitivity and reproducibility of single-plexed ELISA in a multiplexed format.  The technology is designed to meet the needs of scientists who have been unable to find a multiplexing solution that consistently delivers the required performance in their studies.

"Based on feedback gathered over the past several years, scientists in general have been dissatisfied with the performance of earlier generation multiplex systems," said Pete Honkanen, Founder and CEO of Aushon. "They love the idea of what multiplexing can deliver in terms of overall lab productivity, reduced sample consumption and lower cost per study but are seeing relatively poor performance vis-a-vis traditional ELISA...which has constrained the growth in the use of these platforms in the protein biomarker market. We're confident that we've addressed that issue."

Aushon has already placed systems with several early adoptors at Big Pharma and leading academic institutions including Duke University Medical Center. "The initial results demonstrated from Aushon's new system were very encouraging," said Dr. Andrew Nixon, Co-Director of the Phase I Biomarker Laboratory at Duke. "The sensitivity and consistency were equivalent to or better than the singleplex ELISA results for the markers evaluated."

Aushon plans a full global launch in June. The platform will be sold through Aushon's direct sales team in North America and Europe.  In addition, Fisher Scientific is now distributing Aushon's immunoassay products and services in North America, primarily targeting the academic segment.

About Aushon BioSystems

Aushon BioSystems provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development and analysis to leading pharmaceutical, biotechnology, academic and diagnostic clients worldwide. Our unique combination of advanced microarray printing technology, robust biomarker content and an innovative multiplex immunoassay technology platform delivers exceptional performance, quality and reliability that accelerate pre-clinical and clinical biomarker research. Our customers, who include nine of the top ten pharmaceutical companies, trust us to provide the most reliable protein biomarker data available, which lowers cost and improves research productivity. www.aushon.com.

For more information:
Aushon BioSystems
Rocco Raduazo
Vice President, Worldwide Sales
43 Manning Road
Billerica, MA 01821
978-436-6400
Rocco.Raduazo@aushon.com


'/>"/>
SOURCE Aushon BioSystems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
Breaking Medicine Technology:
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):